Usual Adult Dose for Bacteremia

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Endocarditis

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Intraabdominal Infection

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Joint Infection

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Osteomyelitis

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Pneumonia

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Pyelonephritis

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Septicemia

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Bacterial Infection

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Urinary Tract Infection

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Bronchitis

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Pelvic Infections

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Endometritis

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa

Usual Adult Dose for Skin or Soft Tissue Infection

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Use: For the treatment of skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species

Infectious Diseases Society of America (IDSA) Recommendations:

• Incisional surgical site infection: 500 mg IV every 6 hours
• Necrotizing infections of the skin, fascia, and muscle: 1 g IV every 6 to 8 hours

Comments:

• Recommended as a single-drug regimen for treatment of incisional surgical site infections after intestinal or genitourinary tract surgery
• With other agents, recommended as a preferred regimen for the treatment of necrotizing infections of the skin, fascia, and muscle due to mixed infections
• Current guidelines should be consulted for additional information.

Usual Adult Dose for Skin and Structure Infection

If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours

If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours

Use: For the treatment of skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species

Infectious Diseases Society of America (IDSA) Recommendations:

• Incisional surgical site infection: 500 mg IV every 6 hours
• Necrotizing infections of the skin, fascia, and muscle: 1 g IV every 6 to 8 hours

Comments:

• Recommended as a single-drug regimen for treatment of incisional surgical site infections after intestinal or genitourinary tract surgery
• With other agents, recommended as a preferred regimen for the treatment of necrotizing infections of the skin, fascia, and muscle due to mixed infections
• Current guidelines should be consulted for additional information.

Usual Adult Dose for Nosocomial Pneumonia

IDSA and American Thoracic Society Recommendations: 500 mg IV every 6 hours
Duration of therapy: 7 days

Comments:

• With other agents, recommended as an empiric treatment regimen for clinically suspected ventilator-associated pneumonia in units where such coverage is appropriate
• Recommended as initial empiric therapy for hospital-acquired pneumonia (non-ventilator-associated pneumonia)
• Suspected ventilator-associated pneumonia: Dose may need to be reduced in patients less than 70 kg to prevent seizures.
• Current guidelines should be consulted for additional information.

Usual Adult Dose for Peritonitis

International Society for Peritoneal Dialysis (ISPD) Recommendations:
Continuous (all exchanges):

• Loading dose: 250 mg/L intraperitoneally
• Maintenance dose: 50 mg/L intraperitoneally

Intermittent (1 exchange daily): 500 mg intraperitoneally in alternate exchange

Comments:

• Recommended for the treatment of peritoneal dialysis (PD)-related peritonitis
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Bacteremia

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Endocarditis

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Intraabdominal Infection

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Joint Infection

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Osteomyelitis

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Pneumonia

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Pyelonephritis

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Septicemia

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Bacterial Infection

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Urinary Tract Infection

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Skin and Structure Infection

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Bronchitis

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Pelvic Infections

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Endometritis

Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day

Comments:

• Recommended for non-CNS infections

Uses: For the treatment of:

• Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
• Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
• Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
• Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
• Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
• Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
• Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
• Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa

American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day

Comments:

• Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
• In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Peritonitis

ISPD Recommendations:
Continuous:

• Loading dose: 250 mg/L intraperitoneally
• Maintenance dose: 50 mg/L intraperitoneally

Comments:

• Recommended for the treatment of PD-related peritonitis
• Current guidelines should be consulted for additional information.

Renal Dose Adjustments

Adult patients:
If infection suspected/proven due to susceptible bacterial species:

• CrCl at least 90 mL/min: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
• CrCl 60 to less than 90 mL/min: 400 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 6 hours
• CrCl 30 to less than 60 mL/min: 300 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 8 hours
• CrCl 15 to less than 30 mL/min: 200 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 12 hours
• CrCl less than 15 mL/min (not undergoing hemodialysis): Not recommended.

If infection suspected/proven due to bacterial species with intermediate susceptibility:

• CrCl at least 90 mL/min: 1 g (imipenem component) IV every 6 hours
• CrCl 60 to less than 90 mL/min: 750 mg (imipenem component) IV every 8 hours
• CrCl 30 to less than 60 mL/min: 500 mg (imipenem component) IV every 6 hours
• CrCl 15 to less than 30 mL/min: 500 mg (imipenem component) IV every 12 hours
• CrCl less than 15 mL/min (not undergoing hemodialysis): Not recommended.

Pediatric patients less than 30 kg:

• Renal dysfunction: Not recommended.

Comments:

• Adults: The serum creatinine should represent a steady state of renal function; the Cockcroft-Gault method should be used to calculate CrCl.
• Risk of seizures may be increased in adults with CrCl 15 to less than 30 mL/min.
• This drug should not be used in adults with CrCl less than 15 mL/min unless hemodialysis is started within 48 hours.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
Hypersensitivity to either active component or to any of the ingredients

Consult WARNINGS section for additional precautions.

Dialysis

Adult patients:
CrCl less than 15 mL/min undergoing hemodialysis:

• If infection suspected/proven due to susceptible bacterial species: 200 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 12 hours
• If infection suspected/proven due to bacterial species with intermediate susceptibility: 500 mg (imipenem component) IV every 12 hours

Peritoneal dialysis: Data not available

Comments:

• Both components are cleared from circulation during hemodialysis; the patient should receive this drug after hemodialysis and at intervals timed from the end of that hemodialysis session.
• Dialysis patients (especially those with background CNS disease) should be carefully monitored; for patients on hemodialysis, this drug is recommended only when the benefit outweighs the potential risk of seizures.

Other Comments

Administration advice:

• For IV infusion only
• Administer doses up to 500 mg by IV infusion over 20 to 30 minutes; administer doses greater than 500 mg by IV infusion over 40 to 60 minutes; may slow rate of infusion in patients with nausea during administration
• Do not administer reconstituted suspension by direct IV infusion.
• Do not exceed the maximum total daily dose of 4 g/day.

Storage requirements:

• Before reconstitution: Store at 20C to 25C (68F to 77F).
• After reconstitution: This drug maintains satisfactory potency for 4 hours at room temperature or for 24 hours refrigerated (5C); do not freeze solution.

Reconstitution/preparation techniques:

• Diluents containing benzyl alcohol should not be used to reconstitute this drug for use in neonates.
• After reconstitution, the resulting suspension should be transferred to an appropriate infusion solution (before IV infusion).
• The manufacturer product information should be consulted.

IV compatibility:

• Compatible diluents: 0.9% Sodium Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose Injection with 0.225% or 0.45% saline solution
• This drug should not be mixed with, or physically added to, other antibacterial agents; this drug may be administered concomitantly with other antibacterial agents (e.g., aminoglycosides).

General:

• Doses represent the quantity of imipenem; an equal amount of cilastatin is also present.
• Adult dose should be based on suspected/confirmed pathogen susceptibility.
• To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria.
• Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.
• This drug is not indicated in patients with meningitis (safety and efficacy not established).
• This drug is not recommended in pediatric patients with CNS infections due to risk of seizures.

Monitoring:

• General: Organ system functions, including renal, hepatic, and hematopoietic (periodically during prolonged therapy)
• Hematologic: Hematopoietic function (periodically during prolonged therapy)
• Hepatic: Hepatic function (periodically during prolonged therapy)
• Renal: Renal function (periodically during prolonged therapy)

Patient advice:

• Avoid missing doses and complete the entire course of therapy.
• Contact healthcare provider if severe watery or bloody diarrhea develops.